Beta interferon is used to treat:
A- Adult- onset diabetes
B- Hypertension
C- cardiac insufficiency
D- Multiple sclerosis**
E- Ulcers.
Several studies have shown that treating patients with primary symptoms of multiple sclerosis for the first time with interferon beta may lead to a delayed transition to clinically definite clinical status.
The aim of this study was to determine whether the initial treatment with interferon-beta drug limits the complications of the transition to a confirmed case of multiple sclerosis.
In the placebo phase of the double-blind study, BENEFIT, patients with primary symptoms of multiple sclerosis and two signs without clinical parameters detected by magnetic resonance imaging were randomly assigned to be given interferon-beta at a dose of 250 mg (n) = 292) or by placebo (n = 176) by injecting it under the skin every other day and for two years or until clinical polymorphism is diagnosed.
Patients will then be eligible to participate in the next stage in which they will be given an open label administration.
The initial effects of interferon-beta drug were compared in the early stages with its effects when taken after histopathology was diagnosed or after two years of study, during the future analysis plan after three years of random order.
The primary analysis criteria for the ITT analysis were the timing of the diagnosis of clinical multiple sclerosis and EDSS.
A total of 468 patients were randomly assigned, 418 (89%) were enrolled for the follow-up phase and 329 (84%) completed the three-year period following the follow-up phase.
A total of 99 patients (37%) of those with multiple sclerosis were compared with 85 (51%) of late treated patients.
The risk of multiple sclerosis at primary stage was reduced by 41%
(hazard ratio 0 · 59% CI 0.44-0.80; P = 0.0011; absolute risk reduction 14%)
This is compared when the disease is treated late.
Within 3 years, EDSS was confirmed in 42 patients (16%) who were treated in the early stages of the disease and 40 patients (24%) were treated late.
The risk of the disease has been reduced by about 40% compared with late treatment
(0 · 60, 0 · 39-0 · 92; p = 0 · 022; absolute risk reduction 8%).
The FAMSTOI rate was high and balanced in both groups for three years (P = 0.31)
Through previous data, initiation of interferon-beta therapy has been shown to protect against complications of confirmed disability.
And to strengthen its use at the first appearance of symptoms of polymorphic sclerosis.
A- Adult- onset diabetes
B- Hypertension
C- cardiac insufficiency
D- Multiple sclerosis**
E- Ulcers.
Several studies have shown that treating patients with primary symptoms of multiple sclerosis for the first time with interferon beta may lead to a delayed transition to clinically definite clinical status.
The aim of this study was to determine whether the initial treatment with interferon-beta drug limits the complications of the transition to a confirmed case of multiple sclerosis.
In the placebo phase of the double-blind study, BENEFIT, patients with primary symptoms of multiple sclerosis and two signs without clinical parameters detected by magnetic resonance imaging were randomly assigned to be given interferon-beta at a dose of 250 mg (n) = 292) or by placebo (n = 176) by injecting it under the skin every other day and for two years or until clinical polymorphism is diagnosed.
Patients will then be eligible to participate in the next stage in which they will be given an open label administration.
The initial effects of interferon-beta drug were compared in the early stages with its effects when taken after histopathology was diagnosed or after two years of study, during the future analysis plan after three years of random order.
The primary analysis criteria for the ITT analysis were the timing of the diagnosis of clinical multiple sclerosis and EDSS.
A total of 468 patients were randomly assigned, 418 (89%) were enrolled for the follow-up phase and 329 (84%) completed the three-year period following the follow-up phase.
A total of 99 patients (37%) of those with multiple sclerosis were compared with 85 (51%) of late treated patients.
The risk of multiple sclerosis at primary stage was reduced by 41%
(hazard ratio 0 · 59% CI 0.44-0.80; P = 0.0011; absolute risk reduction 14%)
This is compared when the disease is treated late.
Within 3 years, EDSS was confirmed in 42 patients (16%) who were treated in the early stages of the disease and 40 patients (24%) were treated late.
The risk of the disease has been reduced by about 40% compared with late treatment
(0 · 60, 0 · 39-0 · 92; p = 0 · 022; absolute risk reduction 8%).
The FAMSTOI rate was high and balanced in both groups for three years (P = 0.31)
Through previous data, initiation of interferon-beta therapy has been shown to protect against complications of confirmed disability.
And to strengthen its use at the first appearance of symptoms of polymorphic sclerosis.
Labels
Pharma